Table 2. Anterior uveitis flare rates per 100 patient years before and during adalimumab therapy.

Patient groups by history of AU	AU flare rate before adalimumab treatment (flares/100 PYs)	AU flare rate during adalimumab treatment (flares/100 PYs)	Reduction in AU flare rate during adalimumab treatment (%)	p Value*
All patients (n = 1250)	15	7.4	−51	<0.001
History of AU† (n = 274)	68.4	28.9	−58	<0.001
Recent history of AU‡ (n = 106)	176.9	56	−68	<0.001
Symptomatic AU at baseline (n = 28)	192.9	96.2	−50	0.001
Previous chronic uveitis§ (n = 43)	129.1	71.4	−45	0.002

*Wilcoxon signed rank test. †History of AU, history of at least one AU flare anytime. ‡Recent history of AU, history at least one AU flare in the past year. §Chronic uveitis refers to persistent AU flares of at least 3-month duration and with relapse within less than 3 months according to the Standardization of Uveitis Nomenclature Working Group.⁶

AU, anterior uveitis; PYs, patient years.